Vimarsana
Biggest News Aggregation in the World

Page 9 - Genetics Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Research Today - Breaking & Trending Today

Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March - Vimarsana News

Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March

Press release content from PR Newswire. The AP news staff was not involved in its creation. Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March February 11, 2021 GMT (PRNewsfoto/Aruvant Sciences) NEW YORK and BASEL, Switzerland, Feb. 11, 2021 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced management participation in multiple investor and scientific conferences in February and March. The company will be at the ...

Source: apnews.com
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol - Vimarsana News

FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol

Press release content from PR Newswire. The AP news staff was not involved in its creation. FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol February 11, 2021 GMT TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ -- Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LDL-C) In pivotal Phase 3 HoFH trial, adding Evkeeza to standard lipid-lowering therapies reduced LDL-...

Source: apnews.com
Active Motif Partners with Arima Genomics to Launch End-to-End Hi-C Service - Vimarsana News

Active Motif Partners with Arima Genomics to Launch End-to-End Hi-C Service

Press release content from PR Newswire. The AP news staff was not involved in its creation. Active Motif Partners with Arima Genomics to Launch End-to-End Hi-C Service February 9, 2021 GMT SAN DIEGO and CARLSBAD, Calif., Feb. 9, 2021 /PRNewswire/ -- Epigenetics-based research tools and services company, Active Motif, Inc., announced today that it has launched an end-to-end Hi-C service in partnership with Arima Genomics, Inc. to investigate the three-dimensional folding patterns of the genome, providing researchers with greater access to this powerful technology and advancing their research. ...

Source: apnews.com
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene ... - Vimarsana News

Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene ... Amicus Therapeutics, Inc.February 8, 2021 GMT Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease Plan to Submit IND for Next Clinical Study in 2H2021 PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced positive initial results from its first in-human study of its CLN3 Batten disease gene therapy program, AT-GTX-5...

Source: apnews.com
Genprex Announces Formation of Clinical Advisory Board - Vimarsana News

Genprex Announces Formation of Clinical Advisory Board

Press release content from Business Wire. The AP news staff was not involved in its creation. Genprex Announces Formation of Clinical Advisory Board February 8, 2021 GMT AUSTIN, Texas--(BUSINESS WIRE)--Feb 8, 2021-- Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs. Comprised of preeminent clinical specialists, the CAB will lead and ...

Source: apnews.com